In people with diabetes, taking the cholesterol-lowering drug evolocumab for about two years does not lead to changes in blood sugar levels compared to a placebo.

Pro

Against

Mechanism

Synthesis from 1 study

How it works

This drug lowers bad cholesterol without affecting how the body uses insulin or how the pancreas releases it. That’s why blood sugar levels stay the same even after long-term use.

Most probable mechanism

In Simple Terms

Lowering LDL cholesterol with this drug doesn't change how the body uses insulin or how the pancreas releases it, so blood sugar levels stay stable.

Causal chain

Reduction in circulating low-density lipoprotein cholesterol occurs via inhibition of PCSK9-mediated degradation of hepatic LDL receptors

Verified by multiple studies

which leads to

No measurable change in insulin receptor signaling or glucose transporter activity in skeletal muscle, liver, or adipose tissue occurs despite sustained LDL lowering

Supported by evidence

which leads to

Pancreatic beta-cell insulin secretion remains unchanged in response to glucose stimulation during prolonged LDL reduction

Supported by evidence

Evidence from Studies

Supporting (1)

Community contributions welcome

Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial.

Randomized Controlled Trial

Human

Contradicting (0)

Community contributions welcome

No contradicting evidence found

Gold Standard Evidence Needed

According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.

Source Study

Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial.

Score: 73

DOI: 10.1016/S2213-8587(17)30313-3

Similar Assertions

In adults with diabetes who do not have advanced artery disease, a drug called evolocumab lowers LDL cholesterol by about half after 48 weeks of treatment, resulting in significantly lower cholesterol levels compared to a placebo.

87%

In people without diabetes, taking evolocumab for about two years does not raise the likelihood of developing diabetes, even in those with prediabetes. The data show no meaningful change in diabetes risk associated with this cholesterol-lowering drug.

85%

For people with diabetes or clogged arteries who haven’t had a heart attack or stroke yet, taking a drug called evolocumab every two weeks can lower their chance of having a first heart attack, stroke, or heart-related death by about 25% over nearly 5 years.

82%

For people with diabetes who don’t have serious artery disease, adding a drug called evolocumab to their usual cholesterol medicine lowers bad cholesterol a lot — down to 52, compared to 111 without it — after a year.

81%

In adults with diabetes who do not have advanced artery disease, a medication called evolocumab lowers the risk of dying from any cause over five years compared to a placebo.

80%